EUS-Guided Choledochoduodenostomy Versus ERCP for Primary Biliary Decompression in Distal Malignant Biliary Obstruction

NCT ID: NCT04898777

Last Updated: 2024-12-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-01

Study Completion Date

2024-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Malignant biliary obstruction commonly caused by pancreatic adenocarcinoma, cholangiocarcinoma and other etiologies like gallbladder carcinoma, hepatocellular carcinoma, lymphoma, and metastasis to regional solid organs and lymph nodes.

Pancreatobiliary cancers generally present with jaundice, weight loss, and anorexia with significant impact on quality of life, morbidity, and mortality.

The primary goal of diagnosis and management is curative resection but it's difficult due to local invasion and distant metastases at the time of clinical presentation. Biliary decompression helps to reduce symptoms and improve quality of life in patients with malignant biliary obstruction.

Endoscopically placed stents have become the standard of care for non-surgical biliary drainage due to their minimal invasiveness compared to percutaneous drainage.

The standard treatment of obstructive jaundice has been ERCP with biliary stent placement with high success rate in expert hands and low frequency of adverse events.

Endoscopic ultrasound-guided biliary drainage (EUS-BD) has been increasingly used in patients who underwent failed ERCP. EUS-BD can be performed in several ways, choledochoduodenostomy (CDS), hepaticogastrostomy (HGS), antegrade (AG) procedure, and rendezvous (RV) technique.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be a single center, prospective randomized comparative study that includes 50 patients with distal malignant biliary obstruction including pancreatic head masses, distal cholangiocarcinoma or papillary carcinoma.

All patients with inclusion criteria will be recruited in the study by simple random sampling using sealed envelopes until fulfillment of needed sample size for both EUS-BD arm and ERCP-BD arm.

Study tools:

* Informed consent will be obtained from each participant sharing in the study.
* Throughout history taking, complete general examination and local abdominal examination.
* Laboratory investigations: CBC, Serum creatinine, Liver functions tests (AST, ALT and Serum Albumin), Alkaline phosphatase, Serum bilirubin and INR.
* ERCP-BD by papillary approach and EUS-BD by choledochoduodenostomy with transmural stent placement.
* All procedures will be performed under deep sedation or general anesthesia in the left lateral position.
* Procedural time is recorded.
* Technical success is considered after stent placement (expanded and patent) with good bile flow and drainage.
* Follow up:
* Lab investigations will be requested at 2 days, 2 and 4 weeks, 3 and 6 months after the procedure including:

CBC, S.Cr, S.Bil, AST, ALT, S.Alb, ALP and INR.

\- Early adverse events (within 48 hours after procedure) including: Pancreatitis, Cholangitis, Bleeding, Perforation and Peritonitis.

* Late adverse events include stent dysfunction either due to food impaction, tumor ingrowth or stent migration.
* Clinical success is considered at 2 weeks if total bilirubin is less than 50% of baseline and at 4 weeks if total bilirubin is less than 3mg/dL.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Biliary Obstruction

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

ERCP EUS Distal Malignant Biliary Obstruction Choledochoduodenostomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ERCP-BD

ERCP Biliary Drainage by papillary approach with stent placement.

Group Type ACTIVE_COMPARATOR

Biliary drainage

Intervention Type PROCEDURE

Biliary decompression in cases of distal malignant obstruction by stent placement either using ERCP or EUS.

EUS-BD

Endoscopic Ultrasound guided Biliary Drainage by Choledochoduodenostomy with transmural stent placement.

Group Type ACTIVE_COMPARATOR

Biliary drainage

Intervention Type PROCEDURE

Biliary decompression in cases of distal malignant obstruction by stent placement either using ERCP or EUS.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biliary drainage

Biliary decompression in cases of distal malignant obstruction by stent placement either using ERCP or EUS.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Biliary Decompression

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: 18 years and older.
* Presence of locally advanced or metastatic pancreatic head mass on CT or magnetic resonance imaging of the abdomen
* Absence of duodenal obstruction.
* Elevated liver tests with serum bilirubin at least 3 times above the upper limit of normal (1.2 mg/dL).
* Histologic or cytologic diagnosis of malignancy.
* Accept sharing in the study.

Exclusion Criteria

* Age younger than 18 years.
* Pregnancy.
* Hilar biliary obstruction (as the main lesion or coexisting with distal obstruction).
* Presence of duodenal obstruction.
* Histologic or cytologic diagnosis of malignancy.
* Patients underwent previous intervention for biliary drainage.
* Previously failed biliary cannulation at ERCP.
* Prior biliary sphincterotomy or stent placement.
* Surgically altered anatomy or inability to access the major duodenal papilla.
* Patients unfit for anesthesia.
* Patients having uncorrectable coagulopathy or thrombocytopenia.
* History of allergy to radiocontrast agents.
* Refuse sharing in the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mansoura University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ahmed M Gaheen, MSc.

Role: PRINCIPAL_INVESTIGATOR

Mansoura University

Ahmed Y Altonbary, MD

Role: STUDY_DIRECTOR

Mansoura University

Hazem H Alminshawy, Professor

Role: STUDY_DIRECTOR

Mansoura University

Ahmed G Deiab, A.Professor

Role: STUDY_DIRECTOR

Mansoura University

Magdy H Atwa, Professor

Role: STUDY_CHAIR

Mansoura University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Specialized Medical Hospital

Al Mansurah, Dakahlia Governorate, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MD.21.03.437

Identifier Type: -

Identifier Source: org_study_id